Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
AACR Annual meetingAACR Annual meeting
Not Confirmed
Not Confirmed
17-22 April, 2026
Not Confirmed
Not Confirmed
20-22 April, 2026
MAGHREB Pharma ExpoMAGHREB Pharma Expo
Not Confirmed
Not Confirmed
21-23 April, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
AACR Annual meeting
Not Confirmed
Contact SupplierAACR Annual meeting
AACR Annual meetingAACR Annual meeting
Industry Trade Show
Not Confirmed
17-22 April, 2026
Industry Trade Show
Not Confirmed
20-22 April, 2026
MAGHREB Pharma ExpoMAGHREB Pharma Expo
Industry Trade Show
Not Confirmed
21-23 April, 2026
Digital content
NEWS #PharmaBuzz
04 Mar 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/perrigo-to-present-at-the-ubs-global-consumer-and-retail-conference-302702947.html
19 Feb 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/perrigo-announces-quarterly-dividend-302692647.html
13 Feb 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/perrigo-to-release-fourth-quarter-and-fiscal-year-2025-financial-results-on-february-26-2026-302687665.html
21 Jan 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/perrigo-celebrates-national-store-brand-month-by-spotlighting-smarter-over-the-counter-health-and-self-care-choices-302667186.html
18 Nov 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/perrigo-to-attend-morgan-stanley-global-consumer--retail-conference-302618429.html
05 Nov 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/perrigo-to-conduct-strategic-review-of-its-infant-formula-business-302604961.html
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]KDMF
Perrigo API India Private Limited
Registrant Name : Kukjeon Pharmaceutical Co., Ltd.
Registration Date : 2014-12-18
Registration Number : 20141218-28-C-334-18
Manufacturer Name : Perrigo API India Pvt Ltd
Manufacturer Address : Plot No. N-39/N-39-1 Additional MIDC, Anand Nagar, Ambernath (E), District Thane, Mah...
Perrigo API India Private Limited
Registrant Name : Sanil Pharmaceutical Co., Ltd.
Registration Date : 2018-02-09
Registration Number : 20120803-161-I-28-02(11)
Manufacturer Name : Wavelength Enterprises Ltd.
Manufacturer Address : Neot Hovav Eco-Industrial Park, POB 3593, Be'er Sheva 8413502, Israel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
Opill (norgestrel) tablet for nonprescription use to prevent pregnancy the first daily oral contraceptive approved for use in the U.S. without a prescription.
Lead Product(s): Levonorgestrel
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Opill
Study Phase: Approved FDFProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 13, 2023
Lead Product(s) : Levonorgestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves First Nonprescription Daily Oral Contraceptive
Details : Opill (norgestrel) tablet for nonprescription use to prevent pregnancy the first daily oral contraceptive approved for use in the U.S. without a prescription.
Product Name : Opill
Product Type : Hormone
Upfront Cash : Inapplicable
July 13, 2023
Details:
U.S. Food and Drug Administration approved OTC, nicotine coated mint lozenges, works by reducing withdrawal symptoms in consumers who are trying to quit smoking.
Lead Product(s): Nicotine
Therapeutic Area: Psychiatry/Psychology Brand Name: Nicorette-Generic
Study Phase: Approved FDFProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 16, 2023
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Perrigo Announces U.S. FDA Approval for Nicotine Coated Mint Lozenge
Details : U.S. Food and Drug Administration approved OTC, nicotine coated mint lozenges, works by reducing withdrawal symptoms in consumers who are trying to quit smoking.
Product Name : Nicorette-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 16, 2023
Details:
Opill (norgestrel) is a progestin-only daily oral contraceptive, available for over-the-counter (OTC) is used by females of reproductive potential to prevent pregnancy.
Lead Product(s): Levonorgestrel
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Opill
Study Phase: Approved FDFProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 10, 2023
Lead Product(s) : Levonorgestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Joint Advisory Committee Votes in Favor of Perrigo's Opill® Daily Oral Contraceptive for OTC ...
Details : Opill (norgestrel) is a progestin-only daily oral contraceptive, available for over-the-counter (OTC) is used by females of reproductive potential to prevent pregnancy.
Product Name : Opill
Product Type : Hormone
Upfront Cash : Inapplicable
May 10, 2023
Details:
Opill® is a progestin-only daily oral birth control pill (also referred to as a mini pill or non-estrogen pill), which prevents conception by suppressing ovulation.
Lead Product(s): Levonorgestrel
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Opill
Study Phase: Approved FDFProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 28, 2023
Lead Product(s) : Levonorgestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Perrigo Announces New Date for Joint FDA Advisory Committee Meeting to Review Opill® Daily Oral C...
Details : Opill® is a progestin-only daily oral birth control pill (also referred to as a mini pill or non-estrogen pill), which prevents conception by suppressing ovulation.
Product Name : Opill
Product Type : Hormone
Upfront Cash : Inapplicable
March 28, 2023
Details:
Acetaminophen and Ibuprofen acts by inhibiting cyclooxygenases (COX-1 and COX-2), and thus prostaglandins, which are produced by the body in response to injury and inflammation.
Lead Product(s): Paracetamol,Ibuprofen
Therapeutic Area: Neurology Brand Name: Acetaminophen/Ibuprofen-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 01, 2023
Lead Product(s) : Paracetamol,Ibuprofen
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Perrigo Announces FDA Approval of the Store Brand OTC Equivalent of Advil® Dual Action Tablets
Details : Acetaminophen and Ibuprofen acts by inhibiting cyclooxygenases (COX-1 and COX-2), and thus prostaglandins, which are produced by the body in response to injury and inflammation.
Product Name : Acetaminophen/Ibuprofen-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 01, 2023
Details:
Opill® is a progestin-only daily birth control pill (also referred to as a mini pill or non-estrogen pill). If approved, Opill® would be the first ever daily birth control pill available OTC—without a prescription—in the U.S.
Lead Product(s): Levonorgestrel
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Opill
Study Phase: Approved FDFProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 26, 2022
Lead Product(s) : Levonorgestrel
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Perrigo Receives Notification of Postponement for Joint FDA Advisory Committee to Review Opill® D...
Details : Opill® is a progestin-only daily birth control pill (also referred to as a mini pill or non-estrogen pill). If approved, Opill® would be the first ever daily birth control pill available OTC—without a prescription—in the U.S.
Product Name : Opill
Product Type : Hormone
Upfront Cash : Inapplicable
October 26, 2022
Details:
Omeprazole Magnesium Delayed-Release Mini Capsules, 20 mg over-the-counter (OTC),represents a first-to-market mini capsule form of omeprazole, which is indicated for treatment of frequent heartburn.
Lead Product(s): Omeprazole Magnesium
Therapeutic Area: Gastroenterology Brand Name: Omeprazole Magnesium-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 26, 2022
Lead Product(s) : Omeprazole Magnesium
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Perrigo Announces U.S. FDA Approval For Omeprazole Magnesium Delayed-Release Mini Capsules
Details : Omeprazole Magnesium Delayed-Release Mini Capsules, 20 mg over-the-counter (OTC),represents a first-to-market mini capsule form of omeprazole, which is indicated for treatment of frequent heartburn.
Product Name : Omeprazole Magnesium-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 26, 2022
Details:
The approval marks the first branded Rx-to-OTC switch for the company and paves the way for Nasonex® 24HR Allergy (mometasone furoate monohydrate 50mcg) to enter the OTC marketplace.
Lead Product(s): Mometasone Furoate
Therapeutic Area: Immunology Brand Name: Nasonex
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Organon
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 17, 2022
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Organon
Deal Size : Inapplicable
Deal Type : Inapplicable
Perrigo Announces U.S. Fda Approval For Otc Use Of Nasonex® 24hr Allergy
Details : The approval marks the first branded Rx-to-OTC switch for the company and paves the way for Nasonex® 24HR Allergy (mometasone furoate monohydrate 50mcg) to enter the OTC marketplace.
Product Name : Nasonex
Product Type : Steroid
Upfront Cash : Inapplicable
March 17, 2022
Details:
HRA is one of the fastest growing over-the-counter ("OTC") companies globally, with three category-leading self-care brands in blister care (Compeed®), women's health (ellaOne®) and scar care (Mederma®).
Lead Product(s): Ulipristal Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: ellaOne
Study Phase: Approved FDFProduct Type: Miscellaneous
Recipient: HRA Pharma
Deal Size: $2,100.0 million Upfront Cash: $2,100.0 million
Deal Type: Acquisition September 08, 2021
Lead Product(s) : Ulipristal Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Recipient : HRA Pharma
Deal Size : $2,100.0 million
Deal Type : Acquisition
Perrigo to Acquire Leading Consumer Self-Care Company, HRA Pharma
Details : HRA is one of the fastest growing over-the-counter ("OTC") companies globally, with three category-leading self-care brands in blister care (Compeed®), women's health (ellaOne®) and scar care (Mederma®).
Product Name : ellaOne
Product Type : Miscellaneous
Upfront Cash : $2,100.0 million
September 08, 2021
Details:
Adapalene Cream indicated for the topical treatment of acne vulgaris in Perrigo Topical Generic Rx Business.
Lead Product(s): Adapalene
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Altaris Capital Partners
Deal Size: $1,550.0 million Upfront Cash: $1,500.0 million
Deal Type: Divestment March 01, 2021
Lead Product(s) : Adapalene
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Altaris Capital Partners
Deal Size : $1,550.0 million
Deal Type : Divestment
Perrigo To Sell Generic Drugs Business for $1.55 Billion
Details : Adapalene Cream indicated for the topical treatment of acne vulgaris in Perrigo Topical Generic Rx Business.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $1,500.0 million
March 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients
REF. STANDARDS & IMPURITIES
Inspections and registrations
ABOUT THIS PAGE
Omega Pharma Nordic is a supplier offers 2 products (APIs, Excipients or Intermediates).
Find a price of Conjugated Estrogens bulk with DMF offered by Omega Pharma Nordic
Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN ALLEGAN, MICHIGAN. bulk offered by Omega Pharma Nordic
Share 
